Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

41.05 +0.02 (+0.05%)
Official Closing Price Updated: 7:00 PM EST, Nov 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Hims & Hers Health’s Q3 Earnings Call: Our Top 5 Analyst Questions
Hims & Hers Health’s third quarter results prompted a positive market reaction as the company delivered strong revenue growth driven by surging demand for personalized care, new specialty launches, and... 
Via StockStory
Topics Earnings
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
The company continues to have a strong growth outlook ahead. 
Via The Motley Fool
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.
The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned. 
Via Investor's Business Daily
Topics Government
Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years?
Via Stocktwits
Hims & Hers Q3 Preview: GLP-1 Drug Expansion Draws Investor Focus
Via Stocktwits
Earnings Scheduled For November 3, 2025
 
Via Benzinga
Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced
Citi calls Trump’s GLP-1 pricing deal “less bad than feared,” while Needham warns it could erode Hims’ cost advantage. 
Via Stocktwits
Topics Government World Trade
1 Growth Stock to Stash and 2 We Ignore
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. 
Via StockStory
Why Are Hims & Hers Health (HIMS) Shares Soaring Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 6.9% in the morning session after the company reported third-quarter 2025 results that showed strong revenue growth, even as its... 
Via StockStory
Why Hims & Hers Stock May Be a Buy After Mixed Q3 Results
Via MarketBeat
HIMS CEO Says 'A Little Bit of Craziness' Is The Secret To Building A Global Health Platform
Hims & Hers Health (HIMS) CEO Andrew Dudum, sees potential for emotional and medical transformation and plans for global expansion. 
Via Benzinga
HIMS Q3 Deep Dive: Personalized Offerings and Strategic Expansion Shape Telehealth Growth
Telehealth company Hims & Hers Health (NYSE:HIMS) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 49.2% year on year to $599 million. On the other hand, next... 
Via StockStory
Hims & Hers Health Stock Jumps After-Hours As Q3 Growth, Novo Nordisk Talks Fuel Bullish Retail Bets
Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million. 
Via Stocktwits
Topics Earnings
Palantir, Kimberly-Clark, Hims & Hers, Navitas And Cipher Mining: Why These 5 Stocks Are On Investors' Radars Today
PLTR, KMB, HIMS, NVTS, CIFR were among the stocks seen trending among investors on Monday, Nov. 3, 2025. 
Via Benzinga
Hims Hers (HIMS) Q3 2025 Earnings Call Transcript
Hims Hers (HIMS) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Hims & Hers Health (HIMS) Surges After Hours on Robust Q3 and Renewed Novo Nordisk (NVO) Wegovy Talks
Hims & Hers Health (NYSE: HIMS) became a significant after-hours mover on Monday, November 3, 2025, following the release of its third-quarter 2025 financial results and the pivotal announcement of... 
Via MarketMinute
Topics Artificial Intelligence Economy
Hims Says It's Negotiating A New Deal With Novo Nordisk; Shares Surge
Hims & Hers Health said late Monday it's in discussions with Novo Nordisk to sell Wegovy shots. The news buoyed Hims stock. 
Via Investor's Business Daily
Hims & Hers Stock Pops After Q3 Earnings: Here's Why
Here's a look at the Q3 earnings report from Hims & Hers Health. 
Via Benzinga
Hims & Hers Health’s (NYSE:HIMS) Q3 Sales Top Estimates
Telehealth company Hims & Hers Health (NYSE:HIMS) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 49.2% year on year to $599 million. On the other hand, next... 
Via StockStory
Stock Market Today: S&P 500, Dow Jones Futures Rise After Stellar October Gains— Micron Tech, Palantir, Hims & Hers In Focus
U.S. stock futures advanced on Monday after Friday’s positive moves. Futures of major benchmark indices were higher. 
Via Benzinga
Topics Stocks
Hims & Hers Health (HIMS) Q3 Earnings: What To Expect
Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting earnings this Monday afternoon. Here’s what you need to know. 
Via StockStory
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday. 
Via Benzinga
Why Hims & Hers Health (HIMS) Stock Is Trading Up Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 3.4% in the afternoon session after JPMorgan Chase & Co. disclosed in a regulatory filing that it had taken a significant passive... 
Via StockStory
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
1 Profitable Stock on Our Watchlist and 2 We Find Risky
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Topics Retirement
Hims & Hers Short Interest Nears All-Time High, Buy The Dip?
Hims & Hers stock is falling well off its 52-week highs, as bears lean on the CEO's scheduled sale that just took place, though it might be a mistake. 
Via MarketBeat
1 Mid-Cap Stock Worth Your Attention and 2 We Avoid
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks
Here's a look at the most heavily shorted stocks in the market as investors look for the next Beyond Meat. 
Via Benzinga
Short Squeeze Frenzy Fuels October's Market Rebound: A Closer Look at Bearish Bets and Bullish Surges
The U.S. stock market has staged a remarkable recovery in October 2025, with major indices reclaiming lost ground amidst a confluence of positive corporate earnings and improving macroeconomic... 
Via MarketMinute
Topics Economy Stocks World Trade
This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.